Drug Profile
Teriflunomide - Sanofi
Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antivirals; Fluorinated hydrocarbons; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Preclinical Human polyomavirus infections
- No development reported Neurological disorders
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Neurological-disorders in USA (PO, Tablet)
- 22 Apr 2023 Efficacy data from a phase III TERIS trial in Multiple sclerosis presented at the 75th annual meeting of the American academy of neurology 2023 (AAN-2023)
- 04 Oct 2022 Sanofi completes the phase III TERIS trial for Multiple sclerosis in France, Switzerland and Turkey (PO) (NCT03122652)